Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Completed · Phase 2/Phase 3

Conditions studied: Acquired Hemophilia A

In brief

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Key facts

Study ID: NCT01178294
Run by: Baxalta now part of Shire
People needed: 29
Starts: 2010-11-10
Expected to finish: 2013-10-09
Last updated by the study team: 2021-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Written informed consent from subject, trusted person or person who is legally authorized to sign on behalf of the participant (Legal Representative in U.S.), depending on local regulations
Participants with acquired hemophilia with autoimmune inhibitory antibodies to human factor VIII with a clinical diagnosis established by the following criteria: a) Prolonged activated partial thromboplastin time (aPTT), b) Prothrombin time (PT) ≤ upper limit of normal (ULN) + 2 seconds and platelet count within normal range, c) Abnormal aPTT mixing study (patient-normal control 1:1) consistent with a factor VIII inhibitors reduced factor VIII activity level (below 10%)
Has a serious bleeding episode, as documented by the investigator
Be willing and able to follow all instructions and attend all study visits
Participants taking anti-thrombotics (such as clopidogrel, heparin or heparin analogue) may be included provided three half-lives of the agent have elapsed since the last dose of the agent
Life expectancy, prior to onset of the hemorrhagic episode, of at least 90 days
Participants of reproductive age must use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process

You may not qualify if…

Hemodynamically unstable after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy. This hemodynamic instability is characterized by symptomatic hypotension resulting in vital organ dysfunction, such as cardiac ischemia, oliguria (urine volume <0.5 mL/kg in the previous six hours), central nervous system hypoperfusion manifested by mental status change such as confusion (unless head injury or intracranial hemorrhage is present), pulmonary compromise, and/or acidosis (manifested by pH and lactate levels)
Has an established reason for bleeding that is not correctable
Bleeding episode assessed likely to resolve on its own if left untreated
Anti-OBI-1 inhibitor that exceeds 20 Bethesda Units (BU) (prospectively or retrospectively)
Subsequent bleeding episode at the site of the initial qualifying bleeding episode within two weeks following the final OBI-1 dose for the initial qualifying bleeding episode, or subsequent bleeding episode at a different site than the initial qualifying bleeding episode within 1 week following the final OBI-1 dose for the initial qualifying bleeding episode will not be considered "new" qualifying bleeding episodes
Prior history of bleeding disorder other than acquired hemophilia.
Known major sensitivity to therapeutic products of pig or hamster origin; examples include therapeutics of porcine origin (e.g. previously marketed porcine factor VIII, Hyate-C®) and recombinant therapeutics prepared from hamster cells (e.g. Humira®, Advate® and Enbrel®)
Use of hemophilia medication: rFVIIa within 3 hours prior to OBI-1 administration or aPCC treatment within 6 hours prior to OBI-1 administration
Participation in any other clinical study within 30 days of the first OBI-1 treatment
Anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of OBI-1, or whose safety or efficacy may be affected by OBI-1
Is currently pregnant, breastfeeding, or planning to become pregnant or father a child during the study
Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
Inability or unwillingness to comply with the study design, protocol requirements, or the follow-up procedures
Participant of majority age under legal protection

Where it is running

Indiana Hemophilia and Thrombosis Center — Indianapolis, Indiana, United States
Louisiana Center for Bleeding & Clotting Disorders — New Orleans, Louisiana, United States
National Institutes of Health - Warren G. Magnuson Clinical Center — Bethesda, Maryland, United States
Tufts Medical Center — Boston, Massachusetts, United States
Brigham and Women's Hospital — Boston, Massachusetts, United States
University of North Carolina at Chapel Hill Hospital — Chapel Hill, North Carolina, United States
The Pennsylvania State University and Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
Vanderbilt University Medical Center, Hemostasis/Hemophilia Clinic — Nashville, Tennessee, United States
Maisonneuve-Rosemont Hospital — Montreal, Quebec, Canada
Apollo Hospitals — Chennai, Tamil Nadu, India
Royal Free Hospital-Katharine Dormandy Haemophilia Centre and Thrombosis Unit — London, England, United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust — Basingstoke, Hampshire/England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.